BB Biotech Added to SIX Swiss Exchange's SPI ESG Index

BB Biotech AG has been included in the SPI ESG Index of the SIX Swiss Exchange effective September 22, 2025. This development recognizes the investment company's sustained dedication to responsible investing practices and sustainable corporate governance frameworks. The inclusion serves as external validation of BB Biotech's strategic alignment with environmental, social, and governance principles that are increasingly important to modern investors.

Dr. Christian Koch, Head of BB Biotech at Bellevue Asset Management, emphasized the significance of this milestone. "The inclusion in the SPI ESG Index is an important confirmation of our commitment to sustainability," Koch stated. "It also underscores our strategic focus on biotechnology companies that create financial value while making an important contribution to society." This dual focus on financial performance and social impact reflects the growing convergence between investment returns and sustainable business practices in the healthcare sector.

The SPI ESG Index, launched in 2021, comprises companies from the Swiss Performance Index that meet rigorous sustainability criteria assessed by independent agency Inrate. This selection process provides investors with a transparent benchmark for sustainable equity investments within the Swiss market. The index methodology evaluates companies based on comprehensive ESG metrics, ensuring that included entities demonstrate meaningful commitment to sustainable operations. More information about the index framework can be found at https://www.six-group.com.

For BB Biotech, this inclusion enhances visibility among the growing segment of ESG-oriented investors who prioritize companies with demonstrated sustainability credentials. The recognition underscores the long-term attractiveness of BB Biotech's portfolio, which focuses on innovative drug developers primarily headquartered in the United States and Western Europe. As one of the world's largest investors in the biotechnology sector, BB Biotech's ESG recognition signals broader industry trends toward sustainable healthcare investing.

The implications extend beyond immediate visibility benefits. Inclusion in ESG indices often leads to increased institutional investment, as many pension funds and asset managers have mandates requiring ESG-compliant investments. This development may also influence peer companies in the biotechnology sector to strengthen their own ESG practices to remain competitive for capital. The independent assessment by Inrate provides third-party validation of BB Biotech's sustainability claims, addressing growing investor demand for verified ESG performance. Additional details about BB Biotech's investment approach are available at https://www.bbbiotech.com.

This milestone reflects the biotechnology industry's evolving relationship with sustainable investing principles. As healthcare companies face increasing scrutiny regarding their social impact, ESG recognition becomes increasingly important for maintaining investor confidence and accessing capital markets. BB Biotech's inclusion in the SPI ESG Index demonstrates how biotechnology investors can align financial objectives with broader societal benefits, potentially setting a benchmark for the industry's approach to sustainable investment practices.